Literature DB >> 16283095

Neurosarcoidosis. Clinical description of 7 cases with a proposal for a new diagnostic strategy.

Sabrina Marangoni1, Vincenza Argentiero, Bruno Tavolato.   

Abstract

OBJECTIVE: Chronic involvement of the nervous system is relatively rare in sarcoidosis. We describe 7 cases that fulfil Zajicek's criteria for neurosarcoidosis (NS) and propose some modifications to such criteria.
MATERIALS AND METHODS: The patients were admitted for various neurological syndromes: 2 cases presented with chronic lymphocytic meningitis, 4 with spinal cord symptoms, one case was initially confused with multiple sclerosis. Serological tests, immunological screening, cerebrospinal fluid (CSF) analysis, bacteriological and viral testing were performed in all patients. Spinal and cerebral MRI, gallium scan, bronchoscopy with biopsy and bronchoalveolar-lavage fluid analysis, high-resolution computed tomography (HRCT) of the chest, biopsy of the lungs, skin, mediastinal lymph-node and meninges, were useful in diagnosing NS. RESULTS AND DISCUSSION: Laboratory tests showed serum inflammatory abnormalities, but were negative for infectious diseases, while CSF showed inflammatory signs in all patients. MRI revealed meningeal enhancement or hypertrophic pachymeningeal lesions in 4 patients, white matter abnormalities and mass lesions in 2 patients, and a spinal mass lesion in 1 patient. Gallium scan, HRCT, bronchoscopy were positive in most cases. Patients were treated with steroid and immunosuppressive therapy, with improvement in six cases. One patient died from infectious complications.
CONCLUSION: A definite diagnosis of NS requires demonstration of non-caseating granulomas affecting nervous tissues. In most cases, histological evidence of systemic disease (probable NS) is sufficient in the presence of compatible alterations in the CNS. In our patients the bronchoalveolarlavage fluid analysis, gallium scan, and chest HRCT were important for diagnosis, while serum ACE was always normal and chest radiographs were not suggestive of sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16283095     DOI: 10.1007/s00415-005-0043-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  20 in total

Review 1.  Neurosarcoidosis: a review of its intracranial manifestation.

Authors:  D A Nowak; D C Widenka
Journal:  J Neurol       Date:  2001-05       Impact factor: 4.849

2.  Recognition of distinctive patterns of gallium-67 distribution in sarcoidosis.

Authors:  S B Sulavik; R P Spencer; D A Weed; H R Shapiro; S T Shiue; R J Castriotta
Journal:  J Nucl Med       Date:  1990-12       Impact factor: 10.057

Review 3.  [Neurosarcoidosis].

Authors:  C Chapelon-Abric; J M Ziza; J C Piette; O Blétry; B Wechsler; M G Bousser; P Godeau
Journal:  Ann Med Interne (Paris)       Date:  1991

Review 4.  Corticosteroid therapy in pulmonary sarcoidosis: a systematic review.

Authors:  Shanthi Paramothayan; Paul W Jones
Journal:  JAMA       Date:  2002-03-13       Impact factor: 56.272

5.  CD4 and CD8 lymphocyte subsets in cerebrospinal fluid and peripheral blood from patients with multiple sclerosis, meningitis and normal controls.

Authors:  M Vrethem; C Dahle; C Ekerfelt; P Forsberg; O Danielsson; J Ernerudh
Journal:  Acta Neurol Scand       Date:  1998-04       Impact factor: 3.209

6.  Long-term follow-up of neurosarcoidosis.

Authors:  D Ferriby; J de Seze; T Stojkovic; E Hachulla; B Wallaert; A Destée; P Y Hatron; P Vermersch
Journal:  Neurology       Date:  2001-09-11       Impact factor: 9.910

7.  Solitary spinal cord sarcoidosis without other manifestations of systemic sarcoidosis.

Authors:  J H Jaster; F C Dohan; T E Bertorini; J E Bass; K E Mönkemüller; C R Handorf; B E Gerald
Journal:  Clin Imaging       Date:  1997 Jan-Feb       Impact factor: 1.605

8.  The clinical course and prognosis of patients with severe, moderate or mild sarcoidosis.

Authors:  K Takada; Y Ina; M Noda; T Sato; M Yamamoto; M Morishita
Journal:  J Clin Epidemiol       Date:  1993-04       Impact factor: 6.437

9.  Neurosarcoidosis: cerebrospinal fluid lymphocyte subpopulations.

Authors:  B J Stern; D E Griffin; R A Luke; A Krumholz; C J Johns
Journal:  Neurology       Date:  1987-05       Impact factor: 9.910

10.  Central nervous system sarcoidosis--diagnosis and management.

Authors:  J P Zajicek; N J Scolding; O Foster; M Rovaris; J Evanson; I F Moseley; J W Scadding; E J Thompson; V Chamoun; D H Miller; W I McDonald; D Mitchell
Journal:  QJM       Date:  1999-02
View more
  32 in total

1.  Diagnostic pitfalls: a case of neurosarcoidosis mimicking tuberculous meningitis.

Authors:  Franziska Scheibe; Holger Flick; Oliver Wengert; Daniel Wittschieber; Georg Bohner; Peter Ruokonen; Lutz Harms; Klemens Ruprecht; Klemens Angstwurm
Journal:  J Neurol       Date:  2012-02-04       Impact factor: 4.849

2.  Using TNF-alpha antagonist adalimumab for treatment for multisystem sarcoidosis: a case study.

Authors:  Tobias Lahmer; Andreas Knopf; Ines Lanzl; Uwe Heemann; Klaus Thuermel
Journal:  Rheumatol Int       Date:  2011-06-05       Impact factor: 2.631

Review 3.  The challenge of profound hypoglycorrhachia: two cases of sarcoidosis and review of the literature.

Authors:  Harini Sarva; Rachel Chapman; Eghosa Omoregie; Charles Abrams
Journal:  Clin Rheumatol       Date:  2011-08-26       Impact factor: 2.980

4.  Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis.

Authors:  Hela-Felicitas Petereit; Dirk Reske; Hayrettin Tumani; Sven Jarius; F Markus Leweke; Dirk Woitalla; Hans-Walter Pfister; Andrea Rubbert
Journal:  J Neurol       Date:  2010-06-17       Impact factor: 4.849

5.  Neurosarcoidosis.

Authors:  Kenkichi Nozaki; Marc A Judson
Journal:  Curr Treat Options Neurol       Date:  2013-08       Impact factor: 3.598

Review 6.  Extrapulmonary manifestations of sarcoidosis.

Authors:  Deepak A Rao; Paul F Dellaripa
Journal:  Rheum Dis Clin North Am       Date:  2013-03-13       Impact factor: 2.670

7.  Neurosarcoidosis: clinical characteristics, diagnosis, and treatment in eight Chinese patients.

Authors:  Fen Wang; Dongmei Guo; Zheng Liu; Aihong Zhou; Cuibai Wei; Jianping Jia
Journal:  Neurol Sci       Date:  2018-08-07       Impact factor: 3.307

8.  Neurosarcoidosis.

Authors:  Ashok V Patel; David E Stickler; William R Tyor
Journal:  Curr Treat Options Neurol       Date:  2007-05       Impact factor: 3.598

9.  Multiple sclerosis and sarcoidosis: A case for coexistence.

Authors:  Charles Tyshkov; Siddharama Pawate; Michael J Bradshaw; Dorlan J Kimbrough; Tanuja Chitnis; Jeffrey M Gelfand; Lana Zhovtis Ryerson; Ilya Kister
Journal:  Neurol Clin Pract       Date:  2019-06

10.  Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis.

Authors:  José Luis Callejas-Rubio; Lourdes López-Pérez; Norberto Ortego-Centeno
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.